New Guidelines Divide Recommendations for Driver and Nondriver NSCLCJuly 19th 2021
In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.
Clinical Pathways Expanded to Include Data Collection, EHR Management at GeisingerJuly 17th 2021
Clinical pathways in cancer care are beyond the “new” phase, but oncology practices and health systems are still learning all the ways they can bring greater standardization to care, eliminate unnecessary care, improve data collection, and drive value.
Quest for Immune Checkpoint Inhibitor Biomarkers–a Long but Exciting RoadJuly 15th 2021
T-cell–targeted immunomodulators burst onto the scene a decade ago, and investigators turned their focus to immune checkpoints such as CTLA-4, PD-1, and PD-L1 to develop new cancer-fighting strategies.
Epstein Barr Virus T-Cell Therapy Mitigates Challenges of CAR Treatments in LymphomaJuly 14th 2021
Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.
Safety, Efficacy Results Boost the Use of NKT Cells in Pediatric NeuroblastomaJuly 11th 2021
Safety and efficacy data for natural killer T (NKT) cells bolster the use of this cellular therapy in patients with stage IV relapsed/refractory neuroblastoma, according to early findings.
Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 EraJuly 10th 2021
The rapid issuance of clinical trial guidance, trial modifications and emphasis on inclusivity of diverse racial and ethnic patient populations have opened the door for new opportunities for decentralized clinical trials and real-world data in a post-Covid-19 world
Plasma Cell-Free Methylomes Offer Noninvasive Tumor Monitoring Across Cancer SettingsJuly 9th 2021
Th of plasma cell-free methylomes offers investigators a method to monitor tumor responses to treatment noninvasively, according to findings presented during the AACR Annual Meeting 2021.
OS Improves With Addition of Ribociclib/Endocrine Therapy in Advanced Breast CancerJuly 8th 2021
Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Triplet Regimen of Trastuzumab, Pertuzumab, and Paclitaxel Improves pCR, Survival in HER2+ Breast CancerJuly 7th 2021
Adding paclitaxel to the combination of trastuzumab and pertuzumab was associated with pathologic complete response and invasive disease-free survival in patients with HER2-positive breast cancer compared with the doublet alone.
Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast CancerJuly 6th 2021
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.